Cyclic RGD functionalized liposomes targeted to activated platelets for thrombosis dual-mode magnetic resonance...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Radiology

Background:

• Thrombotic disease poses significant health risks, necessitating improved diagnostic methods.
• Current magnetic resonance imaging (MRI) techniques face challenges in rapid and accurate thrombosis detection.
• Nanomaterials offer potential for developing advanced contrast agents for enhanced MRI.

Purpose of the Study:

• To develop and evaluate cyclic RGD functionalized liposomes (cRGD@MLP-Gd) as a dual-mode MRI contrast agent for targeted thrombosis detection.
• To assess the in vitro and in vivo performance of cRGD@MLP-Gd for T1 and T2 MRI contrast enhancement at thrombus sites.

Main Methods:

• Preparation of cRGD@MLP-Gd liposomes encapsulating gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA) and superparamagnetic iron oxide (SPIO).
• Evaluation of in vitro binding to activated platelets and thrombus accumulation.
• In vivo MRI experiments to assess T1 and T2 contrast enhancement dynamics after intravenous administration.

Main Results:

• cRGD@MLP-Gd demonstrated active binding to activated platelets and accumulation at thrombus sites in vitro.
• In vivo studies showed initial T2 contrast enhancement followed by significant T1 enhancement at the thrombus site.
• The dual-mode T1 and T2 enhancement property was confirmed in vivo, indicating active thrombus targeting.

Conclusions:

• cRGD@MLP-Gd exhibits superior characterization and feasibility for rapid thrombosis identification.
• The developed contrast agent enhances MRI sensitivity and accuracy for thrombosis diagnosis.
• This dual-mode MRI approach holds significant potential for improving clinical diagnostic capabilities for thrombotic diseases.